Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 04:20:34时区推断·⟳ 抓取 04:21:06·⚡ 决策 07-29 04:23:31 +2m25s·90.9 天前
Alamar Biosciences推出NULISAseq Immune 340免疫蛋白研究面板
公司发布新的免疫蛋白检测研究面板，方向上有助于扩充NULISA产品线。
📄 原文Investing.com↗ 原文
Alamar Biosciences launches immune profiling panel for research
Dow, S&P 500 end higher on extended oil slide, solid earnings while Nasdaq falls FREMONT, Calif. - Alamar Biosciences I…
不做 Alamar Biosciences（ALMR.US）
常规产品发布稿，无订单金额、客户采购承诺、收入指引或相对市值可量化增量，短线没有明确正期望，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 medium ↗
关键理由
- 公司发布新的免疫蛋白检测研究面板，方向上有助于扩充NULISA产品线。
- 正文未披露订单、客户采购承诺、定价、收入指引或商业化放量节奏，短线难以量化为可交易增量。
主要风险
- 该消息本质是公司产品发布稿，容易被市场视为常规商业进展而非业绩重估催化。
原文全文
展开原文 · 1,877 字
Dow, S&P 500 end higher on extended oil slide, solid earnings while Nasdaq falls
FREMONT, Calif. - Alamar Biosciences Inc. (NASDAQ:ALMR) announced today the launch of the NULISAseq Immune 340 Panel for translational research and drug development.
The panel measures approximately 340 immune-related proteins from a single sample, expanding on the company’s previous Inflammation Panel 250. According to the company, the panel is designed to detect proteins at concentrations ranging from femtograms per milliliter to sub-picograms per milliliter, which the company states are below the detection limits of conventional immunoassays.
The panel targets research applications in cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research. The product measures cytokines, chemokines, checkpoint inhibitors, and cell death pathway markers.
"The immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach," said Dr. Yuling Luo, founder and chief executive officer of Alamar Biosciences.
The company stated the panel addresses detection challenges for immune mediators that circulate at low concentrations in blood, including markers associated with chronic, low-grade inflammation related to aging.
"In drug development, the ability to simultaneously profile the full immune landscape fundamentally changes what we can learn from a single sample," said Bailin Zhang, head of exploratory biomarkers in the Translational Medicine Unit at Sanofi.
Alamar Biosciences is a commercial-stage proteomics company that uses its proprietary NULISA technology and ARGO HT System for protein detection and analysis.
The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
FREMONT, Calif. - Alamar Biosciences Inc. (NASDAQ:ALMR) announced today the launch of the NULISAseq Immune 340 Panel for translational research and drug development.
The panel measures approximately 340 immune-related proteins from a single sample, expanding on the company’s previous Inflammation Panel 250. According to the company, the panel is designed to detect proteins at concentrations ranging from femtograms per milliliter to sub-picograms per milliliter, which the company states are below the detection limits of conventional immunoassays.
The panel targets research applications in cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research. The product measures cytokines, chemokines, checkpoint inhibitors, and cell death pathway markers.
"The immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach," said Dr. Yuling Luo, founder and chief executive officer of Alamar Biosciences.
The company stated the panel addresses detection challenges for immune mediators that circulate at low concentrations in blood, including markers associated with chronic, low-grade inflammation related to aging.
"In drug development, the ability to simultaneously profile the full immune landscape fundamentally changes what we can learn from a single sample," said Bailin Zhang, head of exploratory biomarkers in the Translational Medicine Unit at Sanofi.
Alamar Biosciences is a commercial-stage proteomics company that uses its proprietary NULISA technology and ARGO HT System for protein detection and analysis.
The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。